Tous Actualités
Suivre
Abonner Intercell AG

Intercell AG

EANS-News: Joint Committee on Vaccination and Immunization (JCVI) in the UK broadens Japanese Encephalitis immunization recommendation to include Intercell vaccine

Vienna (Austria), March 4, 2010 (euro adhoc) -

.
 » First country specific recommendation in Europe
 » Key to foster
product awareness for Intercell's vaccine to prevent 
   Japanese 
Encephalitis
  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
Company Information
Subtitle: .
» First country specific recommendation in Europe
» Key to foster product awareness for Intercell's vaccine to prevent
  Japanese Encephalitis
Intercell AG (VSE:
ICLL) today announced that Joint Committee on Vaccination and 
Immunization (JCVI) in the UK has recently updated the Japanese 
Encephalitis chapter of Immunisation against infectious diseases 
("Green Book") to recommend the use of IXIARO® for individuals aged 
18 years and older to protect individuals for high risk of exposure 
during travel or in the course of their occupation. This decision 
follows the expanded recommendations of the US Advisory Committee on 
Immunization Practices (ACIP) in 2009. Further national specific 
recommendations in Europe are expected for the year 2010.
"We are pleased that our joint medical management efforts with our 
partner Novartis are materializing now also in Europe with the first 
country specific recommendations. Especially for novel travel 
vaccines recommendations are key to foster disease and product 
awareness and thus increasing vaccination rates and product uptake," 
stated Gerd Zettlmeissl, Chief Executive Officer of Intercell.
Intercell's novel Japanese Encephalitis vaccine is a purified, 
inactivated vaccine for active immunization of adults against the 
Japanese Encephalitis virus.
end of announcement                               euro adhoc

Further inquiry note:

Intercell AG
Lucia Malfent
Global Head Corporate Communications
Tel. +43 1 20620-1303
communications@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wien / official market

Plus de actualités: Intercell AG
Plus de actualités: Intercell AG